Skip to content
value.today

Phaserx Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2006
Total raised
$13 M
6 rounds on record
Latest round
$4 M
Dec 2015
First round on record
Aug 2009
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Phaserx Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2015$4 MNo. 6$2 to $10 million

Phaserx Inc.: Raise no. 6, Dec 2015

Investors in this round

17 investors had bought by the notice of Dec 29, 2015: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$280,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael W. Houston · Executive Officer
  • Paul W. Johnson · Executive Officer, Director
  • Robert W. Overell · Executive Officer, Director, Promoter
  • Brian W. Atwood · Director
  • John W. Schmidt · Director
  • Richard W. Ulevitch · Director
  • Steven W. Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Palladium Capital Advisors, LLC (CRD 129400) · New York, New YorkSold in CA, FL, ID, NJ, NY, and outside the US

Remarks in the notice

  • On fees: “Palladium Capital Advisors, LLC?s commission calculation is based on the combination of a cash fee and a non-accountable expense allowance.”

Signed by Robert W.Overll, President and chief executive officer. Source: SEC Form D, newest notice filed Dec 29, 2015. Read the notice at the SEC.

debt, optionsSEC
Sep 2013$1 MNo. 5Under $2 million

Phaserx Inc.: Raise no. 5, Sep 2013

Investors in this round

2 investors had bought by the notice of Oct 2, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew W. Leon · Executive Officer
  • Paul W. Johnson · Executive Officer, Director
  • Robert W. Overell · Executive Officer, Director, Promoter
  • Brian W. Atwood · Director
  • John W. Diekman · Director
  • John W. Schmidt · Director
  • Steven W. Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “In addition to Convertible Notes, Issuer is issuing Warrants to purchase shares of capital stock to the Investors. The proceeds to Issuer to be generated upon the exercise of the Warrants will be determined at such time as the warrants become exercisable”

Signed by Robert W. Overell, President and chief executive officer. Source: SEC Form D, newest notice filed Oct 2, 2013. Read the notice at the SEC.

debt, optionsSEC
Dec 2012$2 MNo. 4Under $2 million

Phaserx Inc.: Raise no. 4, Dec 2012

Investors in this round

6 investors had bought by the notice of Dec 21, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew W. Leon · Executive Officer
  • Paul W. Johnson · Executive Officer, Director
  • Robert W. Overell · Executive Officer, Director, Promoter
  • Brian W. Atwood · Director
  • John W. Diekman · Director
  • John W. Schmidt · Director
  • Steven W. Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “In addition to convertible notes, Issuer has issued warrants to purchase shares of capital stock to the Investors. The proceeds to Issuer to be generated upon the exercise of the warrants will be determined at such time as the warrants become exercisable.”

Signed by Robert W. Overell, President and chief executive officer. Source: SEC Form D, newest notice filed Dec 21, 2012. Read the notice at the SEC.

debt, optionsSEC
Jul 2012$2 MNo. 3Under $2 million

Phaserx Inc.: Raise no. 3, Jul 2012

Investors in this round

2 investors had bought by the notice of Jul 6, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew H. Leon · Executive Officer
  • Paul H. Johnson · Executive Officer, Director
  • Robert W. Overell · Executive Officer, Director, Promoter
  • Brian G. Atwood · Director
  • John A. Schmidt · Director
  • John D. Diekman · Director
  • Steven W. Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “In addition to convertible notes, Issuer has issued warrants to purchase shares of capital stock to the Investors. The proceeds to Issuer to be generated upon the exercise of the warrants will be determined at such time as the warrants become exercisable.”

Signed by Robert W. Overell, Ph.D., President & CEO. Source: SEC Form D, newest notice filed Jul 6, 2012. Read the notice at the SEC.

debt, optionsSEC
Feb 2012$4 MNo. 2$2 to $10 million

Phaserx Inc.: Raise no. 2, Feb 2012

Investors in this round

5 investors had bought by the notice of Feb 14, 2012: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew H. Leon · Executive Officer
  • Paul H. Johnson · Executive Officer, Director
  • Robert W. Overell · Executive Officer, Director, Promoter
  • Brian G. Atwood · Director
  • John A. Schmidt · Director
  • John D. Diekman · Director
  • Steven W. Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “In addition to convertible promissory notes, the Company has issued warrants to purchase shares of the Company's capital stock. The warrants have an aggregate exercise price of $1,050,000, representing the total remaining to be sold in the offering.”

Signed by Robert W. Overell, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 14, 2012. Read the notice at the SEC.

debt, optionsSEC
Aug 2009$1 MNo. 1Under $2 million

Phaserx Inc.: Raise no. 1, Aug 2009

Investors in this round

14 investors had bought by the notice of Feb 22, 2010: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew H. Leon · Executive Officer
  • Paul H. Johnson · Executive Officer, Director
  • Raymond H. Calvert · Executive Officer
  • Robert W. Overell · Executive Officer, Director, Promoter
  • Brian G. Atwood · Director
  • John D. Diekman · Director
  • Steven W. Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Reference is made to Form D filed by Issuer on 3/6/08 for aggregate offering amount of $23,030,000 and to Form D filed 8/26/09, for an additional $302,654 in Series A Preferred Stock. This Amendment represents an additional $913,929 in Series A Preferred”

Signed by Robert W. Overell, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 22, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Phaserx Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2015).

    SEC Form D · Dec 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2015

That is all the official record says: Phaserx Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Phaserx Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Phaserx Inc.
NameRoleNamed in
Michael W. HoustonExecutive officerDec 2015
Paul W. JohnsonExecutive officerDec 2015
Robert W. OverellExecutive officerDec 2015
Andrew W. LeonExecutive officerOct 2013
Andrew H. LeonExecutive officerJul 2012
Paul H. JohnsonExecutive officerJul 2012
Raymond H. CalvertExecutive officerFeb 2010
Brian W. AtwoodDirectorDec 2015
John W. SchmidtDirectorDec 2015
Paul W. JohnsonDirectorDec 2015
Richard W. UlevitchDirectorDec 2015
Robert W. OverellDirectorDec 2015
Steven W. GillisDirectorDec 2015
John W. DiekmanDirectorOct 2013
Brian G. AtwoodDirectorJul 2012
John A. SchmidtDirectorJul 2012
John D. DiekmanDirectorJul 2012
Paul H. JohnsonDirectorJul 2012
Robert W. OverellPromoterDec 2015